Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00489307 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dexamethasone for Symptom Burden in Advanced Cancer Patients

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 5 versions Re-verified since Jun 6, 2024, no change to tracked fieldsv29-v33
  2. Start date: Feb 2006 to Feb 2, 2006v28
  3. Primary completion date: Feb 2021 to Feb 28, 2021 Completion date: Feb 2023 to Feb 28, 2028v27 Show all 2 changesShow less
    • Completion date: Feb 2023 to Feb 28, 2028
  4. Completion date: Feb 2022 to Feb 2023v26
  5. Results first posted: Dec 21, 2021 Primary endpoint revised · Enrollment target: estimated 160 to confirmed 132 · Completion date: Feb 2021 to Feb 2022 · 1 morev25 Show all 5 changesShow less
    • Primary endpoint revised
    • Enrollment target: estimated 160 to confirmed 132
    • Completion date: Feb 2021 to Feb 2022
    • Secondary endpoints expanded, about 32 words

    See this version in full on ClinicalTrials.gov ↗

Show 23 earlier versionsHide 23 earlier versions
  1. Primary completion date: Feb 2020 to Feb 2021v24
  2. Completion date: Feb 2020 to Feb 2021v23
  3. Re-verified, no change to tracked fieldsv22
  4. Primary and study completion dates: Feb 2019 to Feb 2020v21
  5. Primary completion date: Feb 2018 to Feb 2019 Completion date: Feb 2019v20 Show all 2 changesShow less
    • Completion date: Feb 2019
  6. Primary completion date: Feb 2017 to Feb 2018v19
  7. Primary completion date: Feb 2015 to Feb 2017 Study sites revised (2) · Collaborators expanded, about 4 wordsv18 Show all 3 changesShow less
    • Study sites revised (2)
    • Collaborators expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  8. Primary endpoint revised Eligibility criteria expanded, about 7 words · Study description expanded, about 6 wordsv17 Show all 3 changesShow less
    • Eligibility criteria expanded, about 7 words
    • Study description expanded, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  9. Primary completion date: Feb 2014 to Feb 2015v16
  10. Primary completion date: Feb 2013 to Feb 2014v15
  11. Re-verified, no change to tracked fieldsv14
  12. Primary completion date: Feb 2012 to Feb 2013 Study description revisedv13 Show all 2 changesShow less
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  13. Trial status: Recruiting to Active, Not Recruiting Enrollment target: 125 to 160 · Site details revised at 2 of 2 sitesv12 Show all 3 changesShow less
    • Enrollment target: 125 to 160
    • Site details revised at 2 of 2 sites
  14. Primary completion date: Feb 2011 to Feb 2012 Study description shortened, about 127 wordsv11 Show all 2 changesShow less
    • Study description shortened, about 127 words

    See this version in full on ClinicalTrials.gov ↗

  15. Study sites revised (2)v10 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  16. Primary completion date: Feb 2010 to Feb 2011 Primary endpoint revisedv9 Show all 2 changesShow less
    • Primary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

  17. Eligibility criteria shortened, about 94 words Study description shortened, about 14 wordsv8 Show all 2 changesShow less
    • Study description shortened, about 14 words

    See this version in full on ClinicalTrials.gov ↗

  18. Primary completion date: Feb 2009 to Feb 2010 Primary endpoint revised · Study description expanded, about 40 wordsv7 Show all 3 changesShow less
    • Primary endpoint revised
    • Study description expanded, about 40 words

    See this version in full on ClinicalTrials.gov ↗

  19. Primary endpoint revised Study description revised · Eligibility criteria shortened, about 2 wordsv6 Show all 3 changesShow less
    • Study description revised
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  20. Study description revisedv5 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  21. Primary endpoint revised Site contacts updated at 1 of 2 sites · Eligibility criteria expanded, about 2 wordsv4 Show all 3 changesShow less
    • Site contacts updated at 1 of 2 sites
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  22. Primary endpoint revised Primary completion date: Feb 2009 · Completion date: Feb 2008 to not stated · Secondary endpoints shortened, about 48 words · 2 morev3 Show all 6 changesShow less
    • Primary completion date: Feb 2009
    • Completion date: Feb 2008 to not stated
    • Secondary endpoints shortened, about 48 words
    • Study description shortened, about 47 words
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  23. Completion date: Feb 2008 Site details revised at 1 of 2 sites · Study arms: 0 to 2 · Eligibility criteria shortened, about 4 wordsv2 Show all 4 changesShow less
    • Site details revised at 1 of 2 sites
    • Study arms: 0 to 2
    • Eligibility criteria shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to learn if dexamethasone can help to control symptoms such as fatigue, pain, nausea, weight loss, loss of appetite, sleep problems, and/or depression in patients with advanced cancer.
Trial Details
NCT Number NCT00489307
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: American Cancer Society, Inc.
Conditions Solid Tumors
Enrollment 132 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov